{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:40:53Z","timestamp":1758282053639,"version":"3.44.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,17]]},"DOI":"10.7759\/cureus.92581","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T03:45:31Z","timestamp":1758167131000},"source":"Crossref","is-referenced-by-count":0,"title":["Symptomatic Congenital Cytomegalovirus Infection in a Preterm Very-Low-Birth-Weight Infant Treated With Intravenous Ganciclovir Followed by Oral Valganciclovir"],"prefix":"10.7759","author":[{"given":"Hiroki","family":"Kita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Nukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsukazu","family":"Mamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004489","article-title":"Clinical practice guidelines for the management of congenital cytomegalovirus infection in japan 2023: executive summary","volume":"43","author":"Ito Y","year":"2024","unstructured":"Ito Y, Morioka I, Takahashi N, et al.. Clinical practice guidelines for the management of congenital cytomegalovirus infection in japan 2023: executive summary. Pediatr Infect Dis J. 2024, 43:e390-6. 10.1097\/INF.0000000000004489","journal-title":"Pediatr Infect Dis J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract14060191","article-title":"Progress and challenges in the management of congenital cytomegalovirus infection","volume":"14","author":"Szulc W","year":"2024","unstructured":"Szulc W, Szyd\u0142owska N, Smyk JM, Majewska A. Progress and challenges in the management of congenital cytomegalovirus infection. Clin Pract. 2024, 14:2445-62. 10.3390\/clinpract14060191","journal-title":"Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133582","article-title":"Oral valganciclovir therapy in infants aged \u22642 months with congenital cytomegalovirus disease: a multicenter, single-arm, open-label clinical trial in Japan","volume":"11","author":"Morioka I","year":"2022","unstructured":"Morioka I, Kakei Y, Omori T, et al.. Oral valganciclovir therapy in infants aged \u22642 months with congenital cytomegalovirus disease: a multicenter, single-arm, open-label clinical trial in Japan. J Clin Med. 2022, 11:14-6. 10.3390\/jcm11133582","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin DW","year":"2008","unstructured":"Kimberlin DW, Acosta EP, S\u00e1nchez PJ, et al.. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008, 197:836-45. 10.1086\/528376","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson WD","year":"2017","unstructured":"Rawlinson WD, Boppana SB, Fowler KB, et al.. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017, 17:177-88. 10.1016\/S1473-3099(17)30143-3","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12122","article-title":"Risk factors for poor outcome in congenital cytomegalovirus infection and neonatal herpes on the basis of a nationwide survey in Japan","volume":"55","author":"Ito Y","year":"2013","unstructured":"Ito Y, Kimura H, Torii Y, et al.. Risk factors for poor outcome in congenital cytomegalovirus infection and neonatal herpes on the basis of a nationwide survey in Japan. Pediatr Int. 2013, 55:566-71. 10.1111\/ped.12122","journal-title":"Pediatr Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin DW","year":"2003","unstructured":"Kimberlin DW, Lin CY, S\u00e1nchez PJ, et al.. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003, 143:16-25. 10.1016\/s0022-3476(03)00192-6","journal-title":"J Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.08.012","article-title":"Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system","volume":"46","author":"Oliver SE","year":"2009","unstructured":"Oliver SE, Cloud GA, S\u00e1nchez PJ, et al.. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009, 46:S22-6. 10.1016\/j.jcv.2009.08.012","journal-title":"J Clin Virol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piac034","article-title":"Ganciclovir and valganciclovir use among infants with congenital cytomegalovirus: data from a multicenter electronic health record dataset in the United States","volume":"11","author":"Leung J","year":"2022","unstructured":"Leung J, Grosse SD, Yockey B, Lanzieri TM. Ganciclovir and valganciclovir use among infants with congenital cytomegalovirus: data from a multicenter electronic health record dataset in the United States. J Pediatric Infect Dis Soc. 2022, 11:379-82. 10.1093\/jpids\/piac034","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin DW","year":"2015","unstructured":"Kimberlin DW, Jester PM, S\u00e1nchez PJ, et al.. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015, 372:933-43. 10.1056\/NEJMoa1404599","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399786-symptomatic-congenital-cytomegalovirus-infection-in-a-preterm-very-low-birth-weight-infant-treated-with-intravenous-ganciclovir-followed-by-oral-valganciclovir","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T03:45:34Z","timestamp":1758167134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399786-symptomatic-congenital-cytomegalovirus-infection-in-a-preterm-very-low-birth-weight-infant-treated-with-intravenous-ganciclovir-followed-by-oral-valganciclovir"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.92581","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}